Eli Lilly's Mirikizumab Maintains Symptomatic Remission for Two Years In Ulcerative Colitis Patients

Eli Lilly And Co LLY has posted new data from the Phase 2 study of mirikizumab in moderately to severely active ulcerative colitis (UC) patients.
Related: Eli Lilly's Mirikizumab Shows Mucosal Healing In Ulcerative Colitis Maintained For Up To One Year.
Patients taking mirikizumab were in symptomatic remission for up to two years.
Among patients on mirikizumab for two years, 85.9% achieved rectal bleeding remission, 84.6% achieved stool frequency remission, and 75.6% of patients were in symptomatic remission.
The safety profile of mirikizumab was consistent with previously published data, and no new safety signals were observed.
In a separate, post-hoc analysis, an absence of bowel urgency at 12 weeks was strongly associated with reduced levels of inflammatory biomarkers, an indicator of disease activity.
Mirikizumab is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of interleukin 23.
Price Action: LLY stock is down 0.79% at $229.20 during the market session on the last check Friday.